Join Growin Stock Community!

Matinas biopharma holdings, inc.MTNB.US Overview

US StockHealthcare
(No presentation for MTNB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MTNB AI Insights

MTNB Overall Performance

MTNB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MTNB Recent Performance

-5.94%

Matinas biopharma holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MTNB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MTNB Key Information

MTNB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MTNB Profile

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Price of MTNB

MTNB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MTNB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
46.50
PB Ratio
0.60
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-316.79%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
46.50
PB Ratio
0.60
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-316.79%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MTNB's latest earnings report released?

    The most recent financial report for Matinas biopharma holdings, inc. (MTNB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MTNB's short-term business performance and financial health. For the latest updates on MTNB's earnings releases, visit this page regularly.

  • How much debt does MTNB have?

    As of the end of the reporting period, Matinas biopharma holdings, inc. (MTNB) had total debt of 2.33M, with a debt ratio of 0.24. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MTNB have?

    At the end of the period, Matinas biopharma holdings, inc. (MTNB) held Total Cash and Cash Equivalents of 5.44M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MTNB's EPS continuing to grow?

    According to the past four quarterly reports, Matinas biopharma holdings, inc. (MTNB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MTNB?

    Matinas biopharma holdings, inc. (MTNB)'s Free Cash Flow (FCF) for the period is -1.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 67.03% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MTNB?

    The latest valuation data shows Matinas biopharma holdings, inc. (MTNB) has a Price-To-Earnings (PE) ratio of -0.43 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.